bevacizumab + serplulimab

Bevacizumab + serplulimab is a **combination therapy** comprised of bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, and serplulimab, a programmed death-1 (PD-1) blocking monoclonal antibody[3][4][6][9]. Bevacizumab inhibits angiogenesis by binding VEGF, thus reducing tumor blood supply and growth[8]. Serplulimab blocks PD-1, enhancing antitumor immune response by preventing cancer-induced T cell inactivation[3]. This combination is used primarily in first-line treatment for **metastatic colorectal cancer**, advanced **hepatocellular carcinoma**, and is under investigation for other solid tumors including non-squamous non-small cell lung cancer with brain metastases[1][3][4][9]. The regimen is administered intravenously and is being developed to improve progression-free survival and overall response rates compared to standard therapies[3][4][6][9].

Other names

bevacizumabserplulimabHLX04HLX-04HLX 04